Try our Advanced Search for more refined results

Expert Analysis

Avoiding Shareholder Class Actions After FDA Drug Denials

By Lisa Dwyer, Michael Biles and Rebecca Matsumura (October 26, 2020, 6:03 PM EDT) -- According to the U.S. Court of Appeals for the First Circuit's opinion in In re: Ariad Pharmaceuticals Inc. Securities Litigation, "When a company's stock declines, a shareholder lawsuit often follows."[1] That maxim rings particularly true for pharmaceutical companies seeking approval from the U.S. Food and Drug Administration for experimental drugs, who often see putative securities class actions filed following an adverse FDA decision....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!